These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29987996)

  • 1. DEFINING INNOVATION WITH RESPECT TO NEW MEDICINES: A SYSTEMATIC REVIEW FROM A PAYER PERSPECTIVE.
    de Solà-Morales O; Cunningham D; Flume M; Overton PM; Shalet N; Capri S
    Int J Technol Assess Health Care; 2018 Jan; 34(3):224-240. PubMed ID: 29987996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative effectiveness and the European pharmaceutical market.
    Jönsson B
    Eur J Health Econ; 2011 Apr; 12(2):97-102. PubMed ID: 21267624
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessing Definitions and Incentives Adopted for Innovation for Pharmaceutical Products in Five High-Income Countries: A Systematic Literature Review.
    Wakutsu N; Hirose E; Yonemoto N; Demiya S
    Pharmaceut Med; 2023 Jan; 37(1):53-70. PubMed ID: 36648749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 5. Defining and Measuring the Affordability of New Medicines: A Systematic Review.
    Antoñanzas F; Terkola R; Overton PM; Shalet N; Postma M
    Pharmacoeconomics; 2017 Aug; 35(8):777-791. PubMed ID: 28477220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NICE and new: appraising innovation.
    Ferner RE; Hughes DA; Aronson JK
    BMJ; 2010 Jan; 340():b5493. PubMed ID: 20051468
    [No Abstract]   [Full Text] [Related]  

  • 7. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
    Gallacher D; Auguste P; Connock M
    Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH.
    Moloney R; Mohr P; Hawe E; Shah K; Garau M; Towse A
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):90-8. PubMed ID: 26168804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
    Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
    Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early assessment of innovation in a healthcare setting.
    Støme LN; Moger T; Kidholm K; Kværner KJ
    Int J Technol Assess Health Care; 2019 Jan; 35(1):17-26. PubMed ID: 30744712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
    MacLeod TE; Harris AH; Mahal A
    Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company.
    Ducournau P; Irl C; Tatt I; McCarvil M; Gyldmark M
    Int J Technol Assess Health Care; 2019 Jan; 35(1):10-16. PubMed ID: 30789111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 19. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial metadata: defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the National Institute for Health Research Health Technology Assessment programme.
    Raftery J; Young A; Stanton L; Milne R; Cook A; Turner D; Davidson P
    Health Technol Assess; 2015 Feb; 19(11):1-138. PubMed ID: 25671821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.